Objective To examine the performance of screening for pre-eclampsia (PE) 
INTRODUCTION
Effective screening for preterm pre-eclampsia (PE) with delivery at < 37 weeks' gestation can be provided at 11-13 weeks by analysis of a combination of maternal demographic characteristics and medical history with measurements of mean arterial pressure (MAP), uterine artery pulsatility index (UtA-PI) and serum placental growth factor (PlGF), with a detection rate (DR) of 75% at a screen-positive rate (SPR) of 10% [1] [2] [3] [4] [5] . Administration of aspirin (150 mg/day from 11-14 weeks' gestation to 36 weeks) in the high-risk group reduces the rate of preterm PE by more than 60% 6 . In contrast, the performance of first-trimester combined screening for term PE is poor, with a DR of 45% at a SPR of 10%, and prophylactic use of aspirin does not reduce the incidence of term PE [1] [2] [3] [4] [5] [6] [7] . Although adverse outcomes for the mother and baby are more serious with preterm PE, the contribution of term PE to such adverse outcomes is at least as high because the condition is three times as common [8] [9] [10] [11] [12] [13] [14] .
The performance of the combined test for term PE is also poor when screening is carried out at 19-24 or 30-34 weeks' gestation 15, 16 . We reported previously that effective screening for term PE may be achieved by a combination of maternal factors, MAP, PlGF and serum soluble fms-like tyrosine kinase-1 (sFlt-1); the DR was 77% (95% CI, 65-87%) at a false-positive rate (FPR) of 10%, but the study population was small (3920 women, including 62 cases of PE) 17 . The rationale for such late third-trimester screening is identification of a high-risk group that would benefit from close monitoring to minimize adverse perinatal events for those who develop PE, by determining the appropriate time and place for delivery 18, 19 . The objective of this prospective observational study in more than 13 000 singleton pregnancies was to examine the performance of screening for late PE by maternal factors and different combinations of biomarkers at 35-37 weeks' gestation.
METHODS
This was a prospective observational study in women attending for a routine hospital visit at 35 + 0 to 36 + 6 weeks' gestation at King's College Hospital, London or Medway Maritime Hospital, Gillingham, UK. We recorded maternal demographic characteristics and medical history, carried out an ultrasound examination for fetal anatomy and growth, measured the left and right UtA-PI by transabdominal color Doppler ultrasound and calculated the mean value of the two arteries 20 , measured MAP by validated automated devices and a standardized protocol 21 , and measured serum concentrations of PlGF and sFlt-1 using an automated biochemical analyzer (Cobas e411 system, Roche Diagnostics, Penzberg, Germany or BRAHMS KRYPTOR compact PLUS, Thermo Fisher Scientific, Hennigsdorf, Germany). Gestational age was determined by the measurement of fetal crown-rump length at 11-13 weeks or fetal head circumference at 19-24 weeks 22, 23 . The women gave written informed consent to participate in the study, which was approved by the NHS Research Ethics Committee.
The outcome measure was PE requiring delivery at any stage after assessment. Data on pregnancy outcome were collected from the hospital maternity records or the general medical practitioners of the women. The obstetric records of all women with pre-existing or pregnancy-associated hypertension were examined to determine the diagnosis of PE. This was based on the finding of hypertension (systolic blood pressure of ≥ 140 mmHg or diastolic blood pressure of ≥ 90 mmHg on at least two occasions 4 h apart developing after 20 weeks' gestation in previously normotensive women) and at least one of the following: proteinuria (≥ 300 mg/24 h or protein-to-creatinine ratio ≥ 30 mg/mmol or ≥ 2+ on dipstick testing), renal insufficiency (serum creatinine > 1.1 mg/dL or two-fold increase in serum creatinine in the absence of underlying renal disease), liver involvement (blood concentration of transaminases twice the normal level), neurological complications (e.g. cerebral or visual symptoms), thrombocytopenia (platelet count < 100 000/μL) or pulmonary edema.
Statistical analysis
Patient-specific risks of delivery with PE at any stage after assessment were calculated using the competing-risks model to combine the prior distribution of gestational age at delivery with PE, obtained from maternal factors, with multiples of the median (MoM) values of MAP, UtA-PI, PlGF and sFlt-1 1 . The performance of screening in the total population and in subgroups of nulliparous and parous women of Afro-Caribbean and Caucasian racial origin were estimated. The original MoM equations [26] [27] [28] [29] have been updated and are reported in Appendix S1. The risk calculator is available freely at the website of The Fetal Medicine Foundation (www.fetalmedicine.com).
The statistical software package R was used for data analyses 30 . The package pROC 31 was used for the receiver-operating characteristics (ROC) curve analysis.
RESULTS
The study population of 13 350 pregnancies included 272 (2.0%) that subsequently developed PE. Maternal and pregnancy characteristics of the study population are summarized in Table 1 . In the PE group, compared to in the unaffected pregnancies, there was a higher median maternal weight, higher incidences of Afro-Caribbean racial origin, assisted conception, family history of PE, chronic hypertension, nulliparity and history of PE, longer interpregnancy interval and lower incidence of smoking. In the PE group, the median MoM values of MAP, UtA-PI and sFlt-1 were increased and PlGF MoM was decreased.
Performance of screening for PE by maternal factors and combinations of biomarkers is shown in Figure 1 and Table 2 . At a risk cut-off of 1 in 20, the SPR was about 10%, but the DR increased significantly from 28% in screening by maternal factors to 53% with the addition of MAP (P < 0.0001), to 67% with the further addition of PlGF (P < 0.0001), and to 70% with the addition of sFlt-1 to maternal factors, MAP and PlGF (P = 0.0001). Addition of UtA-PI did not improve the performance of screening by maternal factors and MAP, maternal factors, MAP and PlGF, or maternal factors, MAP, PlGF and sFlt-1.
The prevalence of PE and performance of screening by maternal factors, MAP, PlGF and sFlt-1 at a risk cut-off of 1 in 20 for nulliparous and parous women of Afro-Caribbean and Caucasian racial origin are given in Table 3 . The prevalence of PE and SPR, FPR and DR were higher in nulliparous than in parous women without a history of PE, and they were higher in parous women with a history of PE than in those without such history, and in those of Afro-Caribbean than in those of Caucasian racial origin. In all groups, the risk of being affected given a screen-positive result was considerably higher than the prevalence of the disease, whereas, in those with a screen-negative result, the risk was reduced considerably.
In the lowest-risk group, Caucasian parous women with no history of PE, which comprised 38% (5093/13 350) of the population and accounted for 16% (43/272) of cases of PE, the DR was 53.5% and the FPR was 4.3%; in total, 221 tests would need to be performed for each true positive identified (5093 tests for 23 cases of PE). In the highest-risk group, Afro-Caribbean women with history of PE, which comprised 0.4% (50/13 350) of the population and accounted for 2.9% (8/272) of cases of PE, the DR was 87.5% and the FPR was 50.0%; in total, seven tests would need to be performed for each true positive identified (50 tests for seven cases of PE).
DISCUSSION

Principal findings
Screening for PE by a combination of maternal factors and biomarkers at 35-37 weeks' gestation can predict 70% of pregnancies that subsequently develop PE, at a FPR of less than 10%. Such a DR is superior to the 28% achieved by screening with maternal factors alone. The performance of screening by both biophysical and biochemical markers is superior to screening by either method alone and the best performance was achieved by inclusion of MAP, PlGF and sFlt-1, with no evidence of improvement by the addition of UtA-PI. *Based on 272 women with PE. FPR, false-positive rate; MAP, mean arterial pressure; PlGF, placental growth factor; sFlt-1, soluble fms-like tyrosine kinase-1; SPR, screen-positive rate; UtA-PI, uterine artery pulsatility index. Data are given as n (%) or n/N (%). *Same as positive predictive value. †Same as 1 -negative predictive value. FPR, false-positive rate; SPR, screen-positive rate.
This study has highlighted that, in screening for PE, the FPR and DR are influenced by the characteristics of the study population and, for a given risk cut-off, they are both higher in nulliparous than in parous women and in those of Afro-Caribbean than Caucasian racial origin. Consequently, comparison of the performance of screening between studies requires the appropriate adjustments for the characteristics of the population under investigation. In all groups, after combined screening, the risk of being affected given a screen-positive result was increased considerably and, if the screen result was negative, the risk was reduced considerably.
Strengths and limitations
The strengths of this late third-trimester screening study for PE are, first, examination of pregnant women attending for routine assessment of fetal growth and wellbeing, second, recording of data on maternal characteristics and medical history to define the prior risk, third, use of a specific methodology and appropriately trained doctors to measure MAP and UtA-PI, fourth, use of automated machines to provide accurate measurement of maternal serum concentration of PlGF and sFlt-1, fifth, expression of the values of the biomarkers as MoMs after adjustment for factors that affect the measurements, and, sixth, use of Bayes' theorem to combine the prior risk with biomarkers to estimate patient-specific risks and the performance of screening for PE.
A potential limitation of the study is that routine ultrasound examination at 35-37 weeks' gestation is not widely available. However, this is likely to change as it becomes more obvious that ultrasound assessment of fetal growth and wellbeing at 35-37 weeks is superior to palpation of the maternal abdomen or measurement of the symphysis-fundal height by a measuring tape or even ultrasound examination at 30-34 weeks, which is the current practice in many countries [32] [33] [34] [35] .
Clinical implications
Screening and diagnosis of PE is based traditionally on the demonstration of elevated blood pressure and proteinuria during a routine clinical visit in the late second or third trimester of pregnancy. In a proposed new pyramid of pregnancy care 36 , an integrated clinic at 22 weeks' gestation, in which biophysical and biochemical markers are combined with maternal factors, aims to estimate the patient-specific risk of developing PE at < 32 and < 36 weeks' gestation and, on the basis of such risk, define the subsequent management of pregnancy, including the timing and content of subsequent visits 37, 38 . However, the performance of screening for term PE by a combination of maternal factors with biomarkers at 22 or 32 weeks' gestation is relatively poor compared to screening at 36 weeks 5-9 and we have therefore proposed that all women, irrespective of whether they had prior screening or not, should have assessment of risk at 35-37 weeks 17, 19 . Combined screening at 35-37 weeks can identify a high-risk group that contains about 70% of pregnancies that will subsequently develop PE; in this group, the risk of PE is considerably higher than in the total population (13% vs 2%). The high-risk group would require measurement of blood pressure and urinalysis on at least a weekly basis and the women should be advised to report any of the symptoms associated with severe PE, such as visual disturbance and epigastric pain. Alternative strategies that merit further investigation include early delivery or pharmacological intervention with pravastatin.
